XOMA Quote, Financials, Valuation and Earnings

Gossamer Bio, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of -362.73%. XOMA Royalty Corp.'s return on equity of 17.31% beat Gossamer Bio, Inc.'s return on equity of -615%.

XOMA Royalty Corp. has a consensus price target of $64.50, signalling upside risk potential of 148.17%. On the other hand Gossamer Bio, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 176.16%. Given that Gossamer Bio, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Gossamer Bio, Inc. is more attractive than XOMA Royalty Corp..

XOMA Royalty Corp. has a beta of 0.941, which suggesting that the stock is 5.919% less volatile than S&P 500. In comparison Gossamer Bio, Inc. has a beta of 1.921, suggesting its more volatile than the S&P 500 by 92.071%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Gossamer Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Gossamer Bio, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are smaller than Gossamer Bio, Inc. quarterly revenues of $13.3M. XOMA Royalty Corp.'s net income of $10.3M is higher than Gossamer Bio, Inc.'s net income of -$48.2M. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 34.86x while Gossamer Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 9.04x versus 17.74x for Gossamer Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rezolute, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of --. XOMA Royalty Corp.'s return on equity of 17.31% beat Rezolute, Inc.'s return on equity of -63.8%.

XOMA Royalty Corp. has a consensus price target of $64.50, signalling upside risk potential of 148.17%. On the other hand Rezolute, Inc. has an analysts' consensus of $4.13 which suggests that it could grow by 50.55%. Given that XOMA Royalty Corp. has higher upside potential than Rezolute, Inc., analysts believe XOMA Royalty Corp. is more attractive than Rezolute, Inc..

XOMA Royalty Corp. has a beta of 0.941, which suggesting that the stock is 5.919% less volatile than S&P 500. In comparison Rezolute, Inc. has a beta of 0.211, suggesting its less volatile than the S&P 500 by 78.913%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Rezolute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Rezolute, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are larger than Rezolute, Inc. quarterly revenues of --. XOMA Royalty Corp.'s net income of $10.3M is higher than Rezolute, Inc.'s net income of -$18.2M. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 34.86x while Rezolute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 9.04x versus -- for Rezolute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vistagen Therapeutics, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of -7525.97%. XOMA Royalty Corp.'s return on equity of 17.31% beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.

XOMA Royalty Corp. has a consensus price target of $64.50, signalling upside risk potential of 148.17%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $0.97 which suggests that it could grow by 32.8%. Given that XOMA Royalty Corp. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe XOMA Royalty Corp. is more attractive than Vistagen Therapeutics, Inc..

XOMA Royalty Corp. has a beta of 0.941, which suggesting that the stock is 5.919% less volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.86%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are larger than Vistagen Therapeutics, Inc. quarterly revenues of $258K. XOMA Royalty Corp.'s net income of $10.3M is higher than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 34.86x while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 9.04x versus 25.55x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of -2.09%. XOMA Royalty Corp.'s return on equity of 17.31% beat Zevra Therapeutics, Inc.'s return on equity of 44.06%.

XOMA Royalty Corp. has a consensus price target of $64.50, signalling upside risk potential of 148.17%. On the other hand Zevra Therapeutics, Inc. has an analysts' consensus of $22.54 which suggests that it could grow by 160.92%. Given that Zevra Therapeutics, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Zevra Therapeutics, Inc. is more attractive than XOMA Royalty Corp..

XOMA Royalty Corp. has a beta of 0.941, which suggesting that the stock is 5.919% less volatile than S&P 500. In comparison Zevra Therapeutics, Inc. has a beta of 1.009, suggesting its more volatile than the S&P 500 by 0.92699999999999%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Zevra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Zevra Therapeutics, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are smaller than Zevra Therapeutics, Inc. quarterly revenues of $26.1M. XOMA Royalty Corp.'s net income of $10.3M is higher than Zevra Therapeutics, Inc.'s net income of -$544K. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 34.86x while Zevra Therapeutics, Inc.'s PE ratio is 13.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 9.04x versus 5.59x for Zevra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.